At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MURA Mural Oncology
Trading 11-05 09:54:42 EST
3.37
-0.03
-1.03%
High3.37
Low3.30
Vol6.87K
Open3.30
D1 Closing3.40
Amplitude1.91%
Mkt Cap57.33M
Tradable Cap46.15M
Total Shares17.04M
T/O22.94K
T/O Rate0.05%
Tradable Shares13.72M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.